Although several studies support that anti-EGFR monoclonal antibodies are not active in colorectal cancer patients with K-RAS gene mutations, it seems that K-RAS mutations have no predictive role in NSCLC patients treated with these agents (O’Byrne et al, 2009; Khambata-Ford et al, 2010), although limited data are available. This evidence concerns the gene KRAS and colorectal cancer.